APR 30, 2020 3:33 PM PDT

Researchers Use AI to Accelerate COVID-19 Drug Development

WRITTEN BY: Annie Lennon

Researchers from the National University of Singapore (NUS) have developed an artificial intelligence platform to accelerate the process of finding drugs for bacterial and viral infections. In particular, they intend to use their system to combat COVID-19. 

The process of developing new drugs in response to the emergence of new bacterial and viral infections usually involves testing a combination of many different, existing drugs. 

Traditional methods make it hard to track how drugs interact due to the millions, if not billions, of possible interactions. Meanwhile, as dosage is decided by trial and error, the process quickly becomes very time-consuming. Then, as these approaches are usually carried out in vitro, there is no guarantee that positive results at the petri dish-level will translate into the human body. Collectively, these factors make drug development time-consuming, costly and extremely laborious. 

To accelerate the process and yield more reliable results, Professor Dean Ho from NUS and his colleagues from Shanghai Jiao Tong University developed an artificial intelligence platform called Identif.AI. It works by using historical data on drug interactions to predict how selected drug candidates will interact, as well as which further tests will be needed. 

To test their platform, the researchers carefully selected 12 drug candidates to treat a lung infection caused by the vesicular stomatitis virus (VSV), and then ran them through the system. Ho says, “Using IDentif.AI, we took three days to identify multiple optimal drug regimens out of billions of possible combinations that reduced the VSV infection to 1.5% with no apparent adverse impact. This speed and accuracy in discovering new drug combination therapies is completely unprecedented.”

Having proven its efficacy, the team now hopes to use the platform to tackle COVID-19. Beyond being able to quickly identify drug candidates and streamline experiments needed to test them, the researchers hope that their system will be able to identify whether different treatments suit different individuals.

“As the development of vaccines and antibody therapies for COVID-19 are ongoing, we will need a rapid therapeutic strategy that addresses the virus which may evolve over time...Our strength is that we can perform one experiment and come out with a list of drug combinations for treatment within days. And in time, if patients do not respond well to the first combinations of drugs, we can derive new combinations within days to re-optimize their care.” says Ho. 


Sources: Futurity, Advanced Therapeutics, Technology Networks 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUL 21, 2020
Cardiology
Investigating New Anti-Blood Clotting Treatments
JUL 21, 2020
Investigating New Anti-Blood Clotting Treatments
When it comes to your cardiovascular health, it is important to look at more than just your heart. The cardiovascular sy ...
AUG 24, 2020
Neuroscience
Researchers Crowdfund $30 Million for Psychedelic Therapy for PTSD
AUG 24, 2020
Researchers Crowdfund $30 Million for Psychedelic Therapy for PTSD
In a historic feat, the Multidisciplinary Association for Psychedelic Studies (MAPS) has raised $30 million to complete ...
AUG 25, 2020
Drug Discovery & Development
The Potential of Antivitamins
AUG 25, 2020
The Potential of Antivitamins
What exactly are antivitamins? They are substances no less that have the power to target the biological function of a ge ...
AUG 22, 2020
Drug Discovery & Development
New Class of Antibiotics Could Treat UTIs
AUG 22, 2020
New Class of Antibiotics Could Treat UTIs
At 11 million cases annually, urinary tract infections (UTIs) are the most common outpatient infections in the U.S., Sci ...
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
SEP 16, 2020
Drug Discovery & Development
Generic Cholesterol-Lowering Drugs Save Money
SEP 16, 2020
Generic Cholesterol-Lowering Drugs Save Money
Generic Cholesterol Drugs Are Saving Money Between 2014 to 2018, there has been a switch from brand name to generic chol ...
Loading Comments...